Idenix Pharmaceuticals (IDIX)

[go seek]

Current Development Status NM283
Two Phase IIb trials
– Treatment-naïve patients
– Treatment-refractory patients
Drug-Drug Interaction study
– Primary PK/PD endpoint at day 36,
study will continue to week 12
followed by 36 weeks of standard of
care
– 90 treatment-naïve patients, 3 arms:
– 200 mg/d NM283 + peg
– 200 mg/d NM283 + peg + weight-based
dosing of RBV
– placebo + peg + weight-based
dosing of RBV - CONTROL

weight-based dosing of RBV? is this SOP?